I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Daniel Brennan raised Thermo Fisher's price target to $675 from $625, maintaining a Buy rating. This adjustment reflects a strengthening recovery, better-than-expected Q2 organic growth, raised full-year guidance, and improving margins across pharma, biotech, industrial, and semiconductor markets. Bank of America Securities also maintained a Buy rating with a $650 target.
Analyst Daniel Brennan from TD Cowen maintained a Buy rating on Thermo Fisher and increased the price target to $675.00 from $625.00.
Daniel Brennan has given his Buy rating due to a combination of factors pointing to a strengthening recovery at Thermo Fisher. The company delivered a solid second quarter with better-than-expected organic growth and raised full-year guidance, signaling that improving trends in pharma, biotech, industrial and semiconductor end markets are now feeding through to results.
Brennan also highlights that Thermo Fisher’s margin performance and earnings power are improving, supporting a higher valuation multiple as demand continues to rebound. Reflecting these dynamics, he increased his price target from $625 to $675, based on stronger forward earnings estimates and confidence that the company can sustain accelerating organic growth over the next several years.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $650.00 price target.